Evidence map›Paper›PMID 27148565›Full record

ArticleCold Spring Harbor molecular case studies2015

De novo mutations in PURA are associated with hypotonia and developmental delay.

Akemi J Tanaka, Renkui Bai, Megan T Cho, Kwame Anyane-Yeboa, Priyanka Ahimaz, Ashley L Wilson, Fran Kendall, Beverly Hay, Timothy Moss, Monica Nardini and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Genes · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. A Colombian Boy with a Novel de novoMolecular syndromology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. InheritedNeurology. Genetics · 2024
    Article
  13. Genes · 2024
    Review
  14. Article
  15. Article
  16. Heterozygous c.175C>T variant inClinical case reports · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Akemi J TanakaDepartment of Pediatrics, Columbia University Medical Center, New York, New York 10029, USA;
Renkui BaiGeneDx, Gaithersburg, Maryland 20877, USA;
Megan T ChoGeneDx, Gaithersburg, Maryland 20877, USA;
Kwame Anyane-YeboaDepartment of Pediatrics, Columbia University Medical Center, New York, New York 10029, USA;
Priyanka AhimazDepartment of Pediatrics, Columbia University Medical Center, New York, New York 10029, USA;
Ashley L WilsonDepartment of Pediatrics, Columbia University Medical Center, New York, New York 10029, USA;
Fran KendallVMP Genetics, Roswell, Georgia 30076, USA;; Department of Kinesiology, University of Georgia, Athens, Georgia 30605, USA;
Beverly HayDivision of Genetics, UMass Memorial Medical Center, Worcester, Massachusetts 01655, USA;
Timothy MossCenter for Personalized Genetic Healthcare, Cleveland Clinic, Cleveland, Ohio 44195, USA;
Monica NardiniCenter for Personalized Genetic Healthcare, Cleveland Clinic, Cleveland, Ohio 44195, USA;
Mislen BauerDepartment of Genetics, Miami Children's Hospital, Miami, Florida 33155, USA;
Kyle RettererGeneDx, Gaithersburg, Maryland 20877, USA;
Jane JuusolaGeneDx, Gaithersburg, Maryland 20877, USA;
Wendy K ChungDepartment of Pediatrics, Columbia University Medical Center, New York, New York 10029, USA;; Department of Medicine, Columbia University Medical Center, New York, New York 10032, USA.
Columbia University Irving Medical Center · USGenVec · USCleveland Clinic · USMiami Children's Hospital · USUMass Memorial Medical Center · USUniversity of Georgia · US

Funding

RESEARCH TRAININGP30DK026687 · NIDDK · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · PI Anthony W Ferrante, DYMPNA GALLAGHER · 1986 to 2026
$33.0M
NIDDK NIH HHS P30 DK026687
6 · The paper itself

Abstract

PURA is the leading candidate gene responsible for the developmental phenotype in the 5q31.3 microdeletion syndrome. De novo mutations in PURA were recently reported in 15 individuals with developmental features similar to the 5q31.3 microdeletion syndrome. Here we describe six unrelated children who were identified by clinical whole-exome sequencing (WES) to have novel de novo variants in PURA with a similar phenotype of hypotonia and developmental delay and frequently associated with seizures. The protein Purα (encoded by PURA) is involved in neuronal proliferation, dendrite maturation, and the transport of mRNA to translation sites during neuronal development. Mutations in PURA may alter normal brain development and impair neuronal function, leading to developmental delay and the seizures observed in patients with mutations in PURA.

Indexed as

central hypotoniageneralized clonic seizuresgeneralized tonic seizuressevere global developmental delay

Identifiers

PMID27148565
PMCPMC4850890
OpenAlexW2337883847

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.